<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="canavan" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">canavan</book-part-id>
      <title-group>
        <title>Canavan Disease</title>
        <alt-title alt-title-type="alt-title">Synonyms: ASPA Deficiency, Aspartoacylase Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Matalon</surname>
            <given-names>Reuben</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Departments of Pediatrics and Biochemistry and Molecular Biology<break/>University of Texas Medical Branch <break/>Galveston, Texas</aff>
          <email>rmatalon@utmb.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Michals-Matalon</surname>
            <given-names>Kimberlee</given-names>
          </name>
          <degrees>PhD, RD</degrees>
          <aff>Department of Health and Human Performance<break/>University of Houston <break/>Houston, Texas</aff>
          <email>kmatalon@uh.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="1999-09-16" date-type="created">
          <day>16</day>
          <month>9</month>
          <year>1999</year>
        </date>
        <date iso-8601-date="2011-08-11" date-type="updated">
          <day>11</day>
          <month>8</month>
          <year>2011</year>
        </date>
        <date iso-8601-date="2006-03-15" date-type="revised">
          <day>15</day>
          <month>3</month>
          <year>2006</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="ced" document-type="chapter">Camurati-Engelmann Disease</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="cantu" document-type="chapter">Cant&#x000fa; Syndrome and Related Disorders</related-object>
      <abstract id="canavan.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Neonatal/infantile (severe) Canavan disease is characterized by macrocephaly, lack of head control, and developmental delays usually noted by age three to five months. As children get older hypotonia becomes severe and failure to achieve independent sitting, ambulation, or speech become apparent. Hypotonia eventually changes to spasticity. Assistance with feeding becomes necessary. Life expectancy is usually into the teens. Mild/juvenile Canavan disease is characterized by mild developmental delay that can go unrecognized. Head circumference may be normal.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of neonatal/infantile Canavan disease relies on demonstration of very high concentration of N-acetylaspartic acid (NAA) in the urine. In mild/juvenile Canavan disease NAA may only be slightly elevated; thus, the diagnosis relies on molecular genetic testing of <italic toggle="yes">ASPA</italic>, the gene encoding the enzyme aspartoacylase.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Neonatal/infantile Canavan disease: Treatment is supportive and directed to providing adequate nutrition and hydration, managing infectious diseases, and protecting the airway. Physical therapy minimizes contractures and maximizes motor abilities and seating posture; special education programs enhance communication skills. Seizures are treated with antiepileptic drugs. Gastrostomy may be needed to maintain adequate food intake and hydration when swallowing difficulties exist.</p>
          <p><italic toggle="yes">Surveillance:</italic> Neonatal/infantile Canavan disease: Follow up every six months to evaluate developmental status and evidence of any new problems.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Canavan disease is inherited in an autosomal recessive manner. Each pregnancy of a couple in which both partners are heterozygous for a pathogenic variant in <italic toggle="yes">ASPA</italic> has a 25% chance of resulting in a child with Canavan disease, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing is available on a population basis for individuals of Ashkenazi Jewish heritage. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible when the pathogenic variants in the family are known. For couples in which one partner is known to be a carrier and the carrier status of the other is unknown, prenatal testing can be performed by measuring the concentration of NAA in amniotic fluid at 16 to 18 weeks&#x02019; gestation.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="canavan.Diagnosis">
        <title>Diagnosis</title>
        <sec id="canavan.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The triad of hypotonia, macrocephaly, and head lag in an infant after age three to five months raises suspicion of neonatal/infantile (severe) Canavan disease. Neuroimaging studies reveal leukodystrophy.</p>
          <p>In individuals with mild/juvenile Canavan disease, neuroimaging may not be helpful.</p>
        </sec>
        <sec id="canavan.Testing">
          <title>Testing</title>
          <p>
            <bold>N-Acetylaspartic acid (NAA)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Urine.</bold> The concentration of NAA in the urine can be measured using gas chromatography-mass spectrometry (GC-MS) [<xref ref-type="bibr" rid="canavan.REF.michals.2011">Michals &#x00026; Matalon 2011</xref>]. Control values in one series (n=48) were 23.5&#x000b1;16.1 &#x000b5;mol/mmol creatinine.</p>
              <list list-type="bullet">
                <list-item>
                  <p>In neonatal/infantile (severe) Canavan disease the mean concentration of NAA (n=117) was 1440.5&#x000b1;873.3 &#x000b5;mol/mmol creatinine.</p>
                </list-item>
                <list-item>
                  <p>In mild/juvenile Canavan disease, mild elevation of NAA may be found, (n=2) 106 &#x000b5;mol/mmol creatinine. Note: Although NAA concentration is also elevated in the blood and CSF of children with neonatal/infantile (severe) Canavan disease, the number of affected individuals evaluated to date is small [<xref ref-type="bibr" rid="canavan.REF.michals.2011">Michals &#x00026; Matalon 2011</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Amniotic fluid.</bold> The concentration of NAA can be measured in the amniotic fluid by stable-isotope dilution and GC-MS or by liquid chromatography tandem mass spectrometry [<xref ref-type="bibr" rid="canavan.REF.bennett.1993.831">Bennett et al 1993</xref>, <xref ref-type="bibr" rid="canavan.REF.aldirbashi.2009.477">Al-Dirbashi et al 2009</xref>]. NAA concentration in amniotic fluid was 0.30-2.55 &#x000b5;mol/L in controls and 8.68 &#x000b5;mol/L in an affected pregnancy [<xref ref-type="bibr" rid="canavan.REF.bennett.1993.831">Bennett et al 1993</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Aspartoacylase enzyme activity</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Skin fibroblasts.</bold> Although aspartoacylase enzyme activity can be assayed in cultured skin fibroblasts, it may not be reliable because the activity varies with culture conditions.</p>
              <list list-type="bullet">
                <list-item>
                  <p>Individuals with severe Canavan disease often have unmeasurable enzyme activity.</p>
                </list-item>
                <list-item>
                  <p>Carriers of alleles associated with severe Canavan disease have about one-half normal enzyme activity [<xref ref-type="bibr" rid="canavan.REF.matalon.1993.744">Matalon et al 1993</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>White blood cells and thrombocytes.</bold> Aspartoacylase enzyme activity is not detectable in white blood cells or platelets.</p>
            </list-item>
            <list-item>
              <p><bold>Amniocytes/CVS.</bold> Aspartoacylase enzyme activity is extremely low in normal amniocytes and chorionic villus sampling (CVS). Enzyme activity cannot be relied upon for prenatal testing [<xref ref-type="bibr" rid="canavan.REF.bennett.1993.831">Bennett et al 1993</xref>].</p>
            </list-item>
          </list>
          <sec id="canavan.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">ASPA</italic> is the only gene in which pathogenic variants are known to cause with Canavan disease.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>
                  <bold>Targeted analysis for pathogenic variants</bold>
                </p>
                <list list-type="bullet">
                  <list-item>
                    <p>Two pathogenic variants, <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Glu285Ala</xref> and <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Tyr231Ter</xref>, account for 98% of pathogenic variants in the Ashkenazi Jewish population and 3% of pathogenic variants in non-Ashkenazi Jewish populations [<xref ref-type="bibr" rid="canavan.REF.michals.2011">Michals &#x00026; Matalon 2011</xref>].</p>
                  </list-item>
                  <list-item>
                    <p>One pathogenic variant, <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Ala305Glu</xref>, accounts for 30%-60% of pathogenic variants in non- Ashkenazi Jewish populations and approximately 1% of pathogenic variants in the Ashkenazi Jewish populations [<xref ref-type="bibr" rid="canavan.REF.kaul.1994b.34">Kaul et al 1994b</xref>, <xref ref-type="bibr" rid="canavan.REF.elpeleg.1999.531">Elpeleg &#x00026; Shaag 1999</xref>].</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p><bold>Sequence analysis</bold> of the <italic toggle="yes">ASPA</italic> coding region is possible for individuals in whom pathogenic variants were not identified by targeted analysis. Note: (1) The <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">c.433-2A&#x0003e;G</xref> splice site variant found in a single Ashkenazi Jewish family should not be considered a typical Ashkenazi Jewish variant. (2) More than 50 other pathogenic variants have been reported in non- Ashkenazi Jewish populations [<xref ref-type="bibr" rid="canavan.REF.kaul.1994b.34">Kaul et al 1994b</xref>, <xref ref-type="bibr" rid="canavan.REF.elpeleg.1999.531">Elpeleg &#x00026; Shaag 1999</xref>, <xref ref-type="bibr" rid="canavan.REF.olsen.2002.e55">Olsen et al 2002</xref>, <xref ref-type="bibr" rid="canavan.REF.zeng.2002.557">Zeng et al 2002</xref>, <xref ref-type="bibr" rid="canavan.REF.michals.2011">Michals &#x00026; Matalon 2011</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Deletion/duplication analysis.</bold> Deletions and duplications are not detectable by sequence analysis; other methods need to be used.</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Deleted segments of various sizes of cDNA have been reported [<xref ref-type="bibr" rid="canavan.REF.zeng.2006.156">Zeng et al 2006</xref>, <xref ref-type="bibr" rid="canavan.REF.kaya.2008.675">Kaya et al 2008</xref>].</p>
                  </list-item>
                  <list-item>
                    <p>The authors encountered two individuals with complete deletion of <italic toggle="yes">ASPA</italic> and two with partial deletions [Matalon, unpublished data].</p>
                  </list-item>
                </list>
              </list-item>
            </list>
            <table-wrap id="canavan.T.summary_of_molecular_genetic_t" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Canavan Disease</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_1">Gene</th>
                    <th id="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_2">Test Method</th>
                    <th id="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_3" rowspan="2" valign="middle" colspan="2" align="left" scope="colgroup" headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_3">Variants Detected</th>
                    <th id="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>1</sup><hr/></th>
                  </tr>
                  <tr>
                    <th headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_4" id="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Ashkenazi Jewish</th>
                    <th headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_4" id="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Non-Ashkenazi Jewish</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">ASPA</italic>
                    </td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">Targeted analysis for pathogenic variants<hr/></td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">Panel&#x000a0;<sup>2</sup><hr/></td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Glu285Ala</xref>, <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Tyr231Ter</xref><hr/></td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_4 hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">98%<hr/></td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_4 hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">3%<hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                      <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Ala305Glu</xref>
                      <hr/>
                    </td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_4 hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">1%<hr/></td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_4 hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">30%-60%<hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>3</sup><hr/></td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" colspan="2" align="left" rowspan="1">Sequence variants<hr/></td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_4 hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">NA<hr/></td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_4 hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">87%<hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" colspan="2" align="left" rowspan="1">Large (multi)exon deletions/duplications</td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_4 hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                    <td headers="hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_1_4 hd_h_canavan.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown (&#x0003c;10%)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>NA = not applicable</p>
                </fn>
                <fn id="canavan.TF.1.1">
                  <label>1. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="canavan.TF.1.2">
                  <label>2. </label>
                  <p>All laboratories use at least a two-variant panel for the Ashkenazi Jewish pathogenic variants; many laboratories use a three-variant panel, and a few use a four-variant panel.</p>
                </fn>
                <fn id="canavan.TF.1.3">
                  <label>3. </label>
                  <p>Examples of variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.</p>
                </fn>
                <fn id="canavan.TF.1.4">
                  <label>4. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="canavan.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband with neonatal/infantile (severe) Canavan disease</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>White matter disease on neuroimaging suggests neonatal/infantile (severe) Canavan disease.</p>
            </list-item>
            <list-item>
              <p>Diagnosis relies on measurement of the concentration of N-acetylaspartic acid (NAA) in the urine using gas chromatography-mass spectrometry (GC-MS). Note: (1) Although NAA concentration is also elevated in the blood and cerebrospinal fluid (CSF) of children with neonatal/infantile (severe) Canavan disease, elevated urine concentration of NAA is sufficient for diagnosis of affected individuals [<xref ref-type="bibr" rid="canavan.REF.michals.2011">Michals &#x00026; Matalon 2011</xref>]. (2) Aspartoacylase enzyme activity may not be reliable in the diagnosis of Canavan disease because enzyme activity fluctuates with culture conditions; therefore, measurement of the urinary concentration of NAA is the preferred diagnostic method [<xref ref-type="bibr" rid="canavan.REF.matalon.1993.744">Matalon et al 1993</xref>].</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing can be used for confirmation of the diagnosis.</p>
              <list list-type="bullet">
                <list-item>
                  <p>In individuals of <bold>Ashkenazi Jewish</bold> ancestry:</p>
                  <list list-type="order">
                    <list-item>
                      <label>1</label>
                      <p>Perform targeted analysis for the two or three common <italic toggle="yes">ASPA</italic> pathogenic variants (<xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Glu285Ala</xref>, <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Tyr231Ter</xref>, and <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Ala305Glu</xref>).</p>
                    </list-item>
                    <list-item>
                      <label>2</label>
                      <p>If neither or only one pathogenic variant in <italic toggle="yes">ASPA</italic> is identified, perform sequence analysis.</p>
                    </list-item>
                    <list-item>
                      <label>3</label>
                      <p>If neither or only one pathogenic variant in <italic toggle="yes">ASPA</italic> is identified on sequence analysis, consider deletion/duplication analysis.</p>
                    </list-item>
                  </list>
                </list-item>
                <list-item>
                  <p>In individuals of <bold>non-Ashkenazi Jewish</bold> ancestry:</p>
                  <list list-type="order">
                    <list-item>
                      <label>1</label>
                      <p>Perform targeted analysis for the <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Ala305Glu</xref> pathogenic variant.</p>
                    </list-item>
                    <list-item>
                      <label>2</label>
                      <p>If neither or only one pathogenic variant in <italic toggle="yes">ASPA</italic> is identified, perform sequence analysis.</p>
                    </list-item>
                    <list-item>
                      <label>3</label>
                      <p>If neither or only one pathogenic variant in <italic toggle="yes">ASPA</italic> is identified on sequence analysis, consider deletion/duplication analysis.</p>
                    </list-item>
                  </list>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>To confirm/establish the diagnosis in a proband with mild/juvenile Canavan disease</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Neuroimaging usually does not indicate leukodystrophy.</p>
            </list-item>
            <list-item>
              <p>Concentration of NAA in the urine is slightly elevated.</p>
            </list-item>
            <list-item>
              <p>Diagnosis must be confirmed by <italic toggle="yes">ASPA</italic> molecular genetic testing in the order described above.</p>
            </list-item>
          </list>
          <p>
            <bold>Carrier testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Testing for at-risk relatives requires prior identification of the pathogenic variants in the family.</p>
            </list-item>
            <list-item>
              <p>Population screening for Ashkenazi Jewish individuals of reproductive age is recommended [<xref ref-type="bibr" rid="canavan.REF.acog_committee_on_genetics.2009.950">ACOG Committee on Genetics 2009</xref>] and typically includes evaluation for the two pathogenic variants common in the Ashkenazi Jewish population.</p>
            </list-item>
          </list>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family. Note: When the family-specific pathogenic variants are not known, prenatal diagnosis of Canavan disease can be accomplished by measuring the concentration of NAA in amniotic fluid.</p>
        </sec>
      </sec>
      <sec id="canavan.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="canavan.Clinical_Description">
          <title>Clinical Description</title>
          <sec id="canavan.NeonatalInfantile_Severe_Canavan">
            <title>Neonatal/Infantile (Severe) Canavan Disease</title>
            <p>Most individuals with Canavan disease have the neonatal/infantile form. Although these infants appear normal early in life, by age three to five months macrocephaly, lack of head control, and developmental delays become apparent. Developmental delay becomes more obvious with increasing age. Children with neonatal/infantile (severe) Canavan disease are especially delayed in their motor skills and are not able to sit, stand, walk, or talk. They learn to interact socially, laugh and smile, reach for objects, and raise their heads in the prone position. They are sometimes irritable. As they get older, hypotonia gives way to spasticity.</p>
            <p>Optic atrophy is present in many children with neonatal/infantile (severe) Canavan disease. However, they are still able to visually track objects. Hearing is usually not impaired.</p>
            <p>As they get older, children with neonatal/infantile (severe) Canavan disease may experience sleep disturbance, seizures, and feeding difficulties. They may require assisted feeding through a nasogastric tube or by a permanent gastrostomy.</p>
            <p>The life expectancy is variable; some children die in the first few years of life, while others survive into their teens or beyond, depending on the clinical course of their disease as well as on the medical and nursing care provided.</p>
          </sec>
          <sec id="canavan.MildJuvenile_Canavan_Disease">
            <title>Mild/Juvenile Canavan Disease</title>
            <p>Children with mild/juvenile Canavan disease may have normal or mildly delayed speech or motor development early in life. If they have a diagnostic work-up for these delays, slightly elevated urinary NAA may be identified and indicate the diagnosis. Generally, these children attend regular school and may benefit from speech therapy or tutoring as needed.</p>
          </sec>
          <sec id="canavan.Neuroimaging">
            <title>Neuroimaging</title>
            <p><bold>Neonatal/infantile (severe) Canavan disease.</bold> CT or MRI performed in infancy may be interpreted as normal [<xref ref-type="bibr" rid="canavan.REF.matalon.2000.d307">Matalon &#x00026; Michals-Matalon 2000</xref>]. Diffuse, symmetric white matter changes are observed in the subcortical areas and in the cerebral cortex; involvement of the cerebellum and brain stem is less marked [<xref ref-type="bibr" rid="canavan.REF.matalon.1995.511">Matalon et al 1995</xref>].</p>
            <p>Ultrasonography shows white matter echogenicity that differs from that of normal brain [<xref ref-type="bibr" rid="canavan.REF.breitbachfaller.2003.96">Breitbach-Faller et al 2003</xref>].</p>
            <p><bold>Mild/juvenile Canavan disease</bold>. Brain MRI does not show general white matter disease. Brain MRI on many children with Canavan disease demonstrates increased signal intensities in the basal ganglia [<xref ref-type="bibr" rid="canavan.REF.surendran.2003.809">Surendran et al 2003</xref>, <xref ref-type="bibr" rid="canavan.REF.yalcinkaya.2005.336">Yalcinkaya et al 2005</xref>, <xref ref-type="bibr" rid="canavan.REF.michals.2011">Michals &#x00026; Matalon 2011</xref>]. Similar changes are observed on MRI of the brain of individuals with mitochondrial diseases [<xref ref-type="bibr" rid="canavan.REF.surendran.2003.809">Surendran et al 2003</xref>, <xref ref-type="bibr" rid="canavan.REF.tacke.2005.252">Tacke et al 2005</xref>, <xref ref-type="bibr" rid="canavan.REF.kurczynski.2011">Kurczynski &#x00026; Victorio 2011</xref>, <xref ref-type="bibr" rid="canavan.REF.michals.2011">Michals &#x00026; Matalon 2011</xref>].</p>
          </sec>
          <sec id="canavan.Neuropathology">
            <title>Neuropathology</title>
            <p>In neonatal / infantile Canavan disease subcortical spongy degeneration is observed. Electron microscopy (EM) reveals swollen astrocytes and distorted mitochondria.</p>
          </sec>
        </sec>
        <sec id="canavan.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Strong genotype-phenotype correlations in Canavan disease have emerged since the measurement of N-acetylaspartic acid (NAA) in the urine and molecular genetic testing of <italic toggle="yes">ASPA</italic> have become routine.</p>
          <sec id="canavan.NeonatalInfantile_Severe_Canavan_1">
            <title>Neonatal/Infantile (Severe) Canavan Disease</title>
            <p>Individuals homozygous for the <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Tyr231Ter</xref> pathogenic variant (who have no enzyme activity) cannot be clinically distinguished from individuals homozygous for the <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Glu285Ala</xref> pathogenic variant (who have some residual enzyme activity).</p>
            <p>The clinical phenotype in individuals homozygous for the <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Ala305Glu</xref> pathogenic variant, most commonly observed in non-Jews (who have no residual enzyme activity), is similar to that observed in individuals homozygous for one of the two pathogenic variants commonly found in the Ashkenazi Jewish population [<xref ref-type="bibr" rid="canavan.REF.matalon.1998.69">Matalon &#x00026; Michals-Matalon 1998</xref>].</p>
            <p>The clinical phenotype in individuals homozygous or compound heterozygous for a large (i.e., multiexon or whole-gene) deletion is severe.</p>
            <list list-type="bullet">
              <list-item>
                <p>Deletion of both <italic toggle="yes">ASPA</italic> alleles causes a severe phenotype [Matalon unpublished data].</p>
              </list-item>
              <list-item>
                <p>An individual homozygous for a 92-kb deletion had a severe phenotype [<xref ref-type="bibr" rid="canavan.REF.zeng.2006.156">Zeng et al 2006</xref>].</p>
              </list-item>
              <list-item>
                <p>Three individuals who were compound heterozygotes for a large deletion (a whole-gene 92-kb deletion, a multiexon 56-kb deletion, and a multiexon 12.3-kb deletion respectively) and a single-nucleotide variant had severe phenotypes [<xref ref-type="bibr" rid="canavan.REF.zeng.2006.156">Zeng et al 2006</xref>].</p>
              </list-item>
            </list>
          </sec>
          <sec id="canavan.MildJuvenile_Canavan_Disease_1">
            <title>Mild/Juvenile Canavan Disease</title>
            <p>Mild/juvenile Canavan disease is associated with at least one &#x0201c;mild&#x0201d; pathogenic variant (p.Tyr288Cys, p.Arg71His, or p.Pro257Arg) with residual ASPA enzyme activity. Individuals are usually heterozygous with one mild variant and one severe variant [<xref ref-type="bibr" rid="canavan.REF.surendran.2003.809">Surendran et al 2003</xref>, <xref ref-type="bibr" rid="canavan.REF.yalcinkaya.2005.336">Yalcinkaya et al 2005</xref>, <xref ref-type="bibr" rid="canavan.REF.kurczynski.2011">Kurczynski &#x00026; Victorio 2011</xref>, <xref ref-type="bibr" rid="canavan.REF.michals.2011">Michals &#x00026; Matalon 2011</xref>].</p>
            <p>&#x0201c;Mild&#x0201d; variants are now more readily recognized by their manifestations of slight increase of NAA in the urine, atypical MRI findings, and associated minor learning difficulties [<xref ref-type="bibr" rid="canavan.REF.surendran.2003.809">Surendran et al 2003</xref>, <xref ref-type="bibr" rid="canavan.REF.tacke.2005.252">Tacke et al 2005</xref>, <xref ref-type="bibr" rid="canavan.REF.kurczynski.2011">Kurczynski &#x00026; Victorio 2011</xref>, <xref ref-type="bibr" rid="canavan.REF.michals.2011">Michals &#x00026; Matalon 2011</xref>].</p>
          </sec>
        </sec>
        <sec id="canavan.Nomenclature">
          <title>Nomenclature</title>
          <p>Other names for neonatal/infantile (severe) Canavan disease that are no longer in use include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Spongy degeneration of the brain (see also <xref ref-type="sec" rid="canavan.Differential_Diagnosis">Differential Diagnosis</xref>)</p>
            </list-item>
            <list-item>
              <p>Van Bogaert and Bertrand disease</p>
            </list-item>
          </list>
        </sec>
        <sec id="canavan.Prevalence">
          <title>Prevalence</title>
          <p>While Canavan disease occurs in all ethnic groups, most reported individuals are of Ashkenazi Jewish origin.</p>
          <p>Carrier frequency has varied depending on the source of samples:</p>
          <list list-type="bullet">
            <list-item>
              <p>Screening of Ashkenazi Jewish individuals for the two common Ashkenazi Jewish pathogenic variants revealed a carrier rate of 1:40 [<xref ref-type="bibr" rid="canavan.REF.kronn.1995.1250">Kronn et al 1995</xref>, <xref ref-type="bibr" rid="canavan.REF.matalon.1995.511">Matalon et al 1995</xref>].</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="canavan.REF.sugarman.2001.s38">Sugarman &#x00026; Allitto [2001]</xref> found a carrier rate of 1:58 when testing for the three most common alleles in the Ashkenazi Jewish population.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="canavan.REF.feigenbaum.2004.142">Feigenbaum et al [2004]</xref> found a carrier rate of 1:57. Based on these carrier rates, the a priori risk for affected children in the Ashkenazi Jewish population is about 1:6,400 to 1:13,456.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="canavan.REF.fares.2008.236">Fares et al [2008]</xref> found a carrier rate of 1:82 in an Ashkenazi Jewish population.</p>
            </list-item>
          </list>
          <p>The carrier rate in non-Jews is not known; however, it is assumed to be much lower than the carrier rate in the Ashkenazi Jewish population.</p>
        </sec>
      </sec>
      <sec id="canavan.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other neurodegenerative disorders of infancy that are associated with a normal or large head size include <related-object link-type="booklink" source-id="gene" document-id="alexander" document-type="chapter">Alexander disease</related-object>, <related-object link-type="booklink" source-id="gene" document-id="tay-sachs" document-type="chapter">Tay-Sachs disease</related-object>, <related-object link-type="booklink" source-id="gene" document-id="mld" document-type="chapter">metachromatic leukodystrophy</related-object>, and glutaricacidemia type 1. <xref ref-type="sec" rid="canavan.Testing">Laboratory testing</xref> or <xref ref-type="sec" rid="canavan.Molecular_Genetic_Testing">molecular genetic testing</xref> can be used to distinguish neonatal/infantile (severe) Canavan disease from these disorders.</p>
        <p>Spongy degeneration of the brain can be found in viral infections, in mitochondrial disorders, particularly <related-object link-type="booklink" source-id="gene" document-id="narp" document-type="chapter">Leigh syndrome</related-object> (see also <related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial Disorders Overview</related-object>), and in metabolic disorders such as <related-object link-type="booklink" source-id="gene" document-id="nkh" document-type="chapter">glycine encephalopathy</related-object> (nonketotic hyperglycinemia).</p>
        <p>Mild/juvenile Canavan disease may be misdiagnosed as a mitochondrial disorder (see <related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial Disorders Overview</related-object>).</p>
      </sec>
      <sec id="canavan.Management">
        <title>Management</title>
        <sec id="canavan.Evaluations_Following_Initial_Di">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with neonatal/infantile (severe) Canavan disease, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Brain MRI</p>
            </list-item>
            <list-item>
              <p>Developmental assessment</p>
            </list-item>
            <list-item>
              <p>Nutritional assessment</p>
            </list-item>
          </list>
        </sec>
        <sec id="canavan.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>
            <bold>Neonatal/infantile Canavan disease</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Treatment is supportive and directed to providing adequate nutrition and hydration, managing infectious diseases, and protecting the airway.</p>
            </list-item>
            <list-item>
              <p>Children benefit from physical therapy to minimize contractures and to maximize abilities and seating posture, from other therapies to enhance communication skills (especially in those with a more gradual clinical course), and from early intervention and special education programs.</p>
            </list-item>
            <list-item>
              <p>Seizures may be treated with antiepileptic drugs (AEDs).</p>
            </list-item>
            <list-item>
              <p>A feeding gastrostomy may be required to maintain adequate intake and hydration in the presence of swallowing difficulties.</p>
            </list-item>
            <list-item>
              <p>Diamox<sup>&#x000ae;</sup> seems to reduce intracranial pressure.</p>
            </list-item>
            <list-item>
              <p>Botox<sup>&#x000ae;</sup> injections may be used to relieve spasticity.</p>
            </list-item>
          </list>
          <p><bold>Mild/juvenile Canavan disease.</bold> These individuals may require speech therapy or tutoring but require no special medical care.</p>
        </sec>
        <sec id="canavan.Prevention_of_Secondary_Complica">
          <title>Prevention of Secondary Complications</title>
          <p>
            <bold>Neonatal/infantile Canavan disease</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Contractures and decubiti need to be prevented by exercise and position changes.</p>
            </list-item>
            <list-item>
              <p>Feeding difficulties and seizures increase the risk of aspiration, which can be reduced with use of a G-tube for feeding.</p>
            </list-item>
          </list>
        </sec>
        <sec id="canavan.Surveillance">
          <title>Surveillance</title>
          <p><bold>Neonatal/infantile Canavan disease.</bold> Follow up at six-month intervals to evaluate developmental status and evidence of any new problems is suggested.</p>
          <p><bold>Mild/juvenile Canavan disease.</bold> Annual routine follow up is indicated.</p>
        </sec>
        <sec id="canavan.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="canavan.Related_Genetic_Counseling_Issue">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="canavan.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>
            <bold>Humans</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Gene transfer to the brains of two children with Canavan disease using a nonviral vector was well tolerated [<xref ref-type="bibr" rid="canavan.REF.leone.2000.27">Leone et al 2000</xref>, <xref ref-type="bibr" rid="canavan.REF.janson.2002.1391">Janson et al 2002</xref>]. Some biochemical, radiologic, and clinical changes may have occurred; however, the children continued to follow the course of those with untreated Canavan disease.</p>
            </list-item>
            <list-item>
              <p>In ten children with Canavan disease, multisite injection with AAV2 as the vector for ASPA was well tolerated [<xref ref-type="bibr" rid="canavan.REF.mcphee.2006.577">McPhee et al 2006</xref>]. Three developed AAV2 neutralizing antibodies. No children improved.</p>
            </list-item>
            <list-item>
              <p>Lithium citrate may reduce N-acetylaspartic acid (NAA) concentration in the brain. Six persons with Canavan disease given lithium citrate for 60 days were reported to have reduced NAA in the basal ganglia and mild improvement in frontal white matter [<xref ref-type="bibr" rid="canavan.REF.assadi.2010.354">Assadi et al 2010</xref>]. The clinical significance of use of lithium citrate is not known.</p>
            </list-item>
            <list-item>
              <p>The enzyme defect in Canavan disease leads to decreased levels of acetate in the brain. In a clinical trial with glycerol triacetate in two persons with Canavan disease the compound was well tolerated; however, there was no clinical improvement [<xref ref-type="bibr" rid="canavan.REF.madhavarao.2009.640">Madhavarao et al 2009</xref>]. It is speculated that higher doses of glycerol triacetate may be needed.</p>
            </list-item>
          </list>
          <p>
            <bold>Animal models</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>A knock-out mouse has been created, with a phenotype similar to that of human Canavan disease [<xref ref-type="bibr" rid="canavan.REF.matalon.2000.165">Matalon et al 2000</xref>]. This model is being used to investigate pathophysiology [<xref ref-type="bibr" rid="canavan.REF.surendran.2004.19">Surendran et al 2004</xref>] gene therapy and other modes of treatment [<xref ref-type="bibr" rid="canavan.REF.matalon.2003.580">Matalon et al 2003</xref>].</p>
              <list list-type="bullet">
                <list-item>
                  <p>Gene therapy with AAV2 was given to knock-out Canavan disease mice: localized improvement did not spread to the entire brain [<xref ref-type="bibr" rid="canavan.REF.matalon.2003.580">Matalon et al 2003</xref>].</p>
                </list-item>
                <list-item>
                  <p>Stem cell therapy in knock-out Canavan disease mice was done in collaboration with Genzyme Corporation: The stem cells produced some oligodendrocytes but not enough to make myelin [<xref ref-type="bibr" rid="canavan.REF.surendran.2004.19">Surendran et al 2004</xref>].</p>
                </list-item>
                <list-item>
                  <p>Enzyme replacement therapy using native ASPA and pegylated ASPA (i.e., ASPA in which covalent attachment of polyethylene glycol polymer chains masks the enzyme from the host allowing for longer circulation and less renal clearance) were injected into the peritoneum of Canavan disease mice. Preliminary results show that the enzyme passed the blood brain barrier and there was a decrease of NAA in the brain. These experiments were short term; longitudinal studies are being planned [<xref ref-type="bibr" rid="canavan.REF.zano.2011.176">Zano et al 2011</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>A mouse that seems to have a Canavan disease phenotype was produced by using the mutagen ethylenenitrosourea (ENU) to change the residue Gln193 to a termination codon in exon 4 (577C&#x0003e;T) [<xref ref-type="bibr" rid="canavan.REF.traka.2008.11537">Traka et al 2008</xref>].</p>
            </list-item>
          </list>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="canavan.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="canavan.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Canavan disease is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="canavan.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes; each therefore carries a single copy of a pathogenic variant in <italic toggle="yes">ASPA</italic>.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. The phenotype is consistent within families.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> No severely affected person has been known to reproduce. Individuals with mild/juvenile Canavan disease could reproduce; this has not been reported to date.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="canavan.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Molecular genetic testing can be used to identify carriers among at-risk family members once the pathogenic variants are identified in the family.</p>
          <p>Carrier detection using biochemical assay is not routinely possible because it relies on a complex enzyme assay in cultured skin fibroblasts.</p>
        </sec>
        <sec id="canavan.Population_Screening">
          <title>Population Screening</title>
          <p><bold>Individuals of Ashkenazi Jewish heritage.</bold> Because of the relatively increased carrier rate in Ashkenazi Jews and the availability of genetic counseling and prenatal diagnosis, population screening has been initiated for Ashkenazi Jewish individuals of reproductive age in some states and is recommended in published guidelines (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acmg.net/StaticContent/StaticPages/Canavan.pdf">American College of Medical Genetics</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/10390111">American College of Obstetricians and Gynecologists</ext-link>) [<xref ref-type="bibr" rid="canavan.REF.acog_committee_on_genetics.2009.950">ACOG Committee on Genetics 2009</xref>]. Through this type of screening program, couples in which both partners are carriers can be made aware of their status and risks before having affected children. Then, through genetic counseling and the option of prenatal testing, such families can, if they choose, bring to term only those pregnancies in which the fetus is unaffected. In population screening of people of Ashkenazi Jewish heritage, a panel of the two or three common <italic toggle="yes">ASPA</italic> pathogenic variants (<xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Glu285Ala</xref>, <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Tyr231Ter</xref>, and <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">p.Ala305Glu</xref>) can be expected to identify 99% of heterozygotes.</p>
          <p><bold>Assisted reproductive technologies.</bold> Individuals who are pursuing reproductive technologies that involve gamete (egg or sperm) donation and who are at increased risk of being heterozygous for an <italic toggle="yes">ASPA</italic> pathogenic variant because of family history or ethnic background should be offered screening. If the gamete recipient is a carrier, potential gamete donors can be screened to determine carrier status.</p>
        </sec>
        <sec id="canavan.Related_Genetic_Counseling_Issue">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="canavan.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p><bold>Molecular genetic testing.</bold> Prenatal testing for pregnancies at 25% risk is possible by analysis of DNA extracted from fetal cells obtained by chorionic villus sampling (CVS) at approximately ten to 12 weeks' gestation or by amniocentesis usually performed at approximately 15 to 18 weeks' gestation. Both pathogenic variants present in the family must be identified before prenatal testing can be performed.</p>
          <p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p>
          <p><bold>Biochemical genetic testing.</bold> For couples in which one partner is known to be a carrier and the genetic status of the other is unknown, prenatal testing can be performed by measuring the level of NAA in amniotic fluid at 15 to 18 weeks&#x02019; gestation [<xref ref-type="bibr" rid="canavan.REF.bennett.1993.831">Bennett et al 1993</xref>, <xref ref-type="bibr" rid="canavan.REF.aldirbashi.2009.477">Al-Dirbashi et al 2009</xref>].</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be available for families in which the pathogenic variants have been identified [<xref ref-type="bibr" rid="canavan.REF.yaron.2005.465">Yaron et al 2005</xref>].</p>
        </sec>
      </sec>
      <sec id="canavan.Resources">
        <title>Resources</title>
      </sec>
      <sec id="canavan.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold> The gene comprises 29 kb with six exons and five introns. The exons vary in size from 94 bp (exon 3) to 514 bp (exon 6). For a detailed summary of gene and protein information, see, <related-object source-id="gene" document-id="canavan" object-id="canavan.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> See <xref ref-type="table" rid="canavan.T.selected_aspa_pathogenic_varia">Table 2</xref>. The major pathogenic variants are p.Glu285Ala, p.Tyr231Ter, and p.Ala305Glu. (For more information, see <related-object source-id="gene" document-id="canavan" object-id="canavan.molgen.TA">Table A</related-object>.)</p>
        <table-wrap id="canavan.T.selected_aspa_pathogenic_varia" position="anchor" orientation="portrait">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">ASPA</italic> Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.433-2A&#x0003e;G<hr/></td>
                <td headers="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--<hr/></td>
                <td headers="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_3" rowspan="5" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000049.2">NM_000049.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000040.1">NP_000040.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.693C&#x0003e;A<hr/></td>
                <td headers="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr231Ter<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.854A&#x0003e;C<hr/></td>
                <td headers="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu285Ala<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.863A&#x0003e;G<hr/></td>
                <td headers="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr288Cys<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.914C&#x0003e;A</td>
                <td headers="hd_h_canavan.T.selected_aspa_pathogenic_varia_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala305Glu</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> Aspartoacylase is a protein of 313 amino acids, suggesting a molecular weight of 36 kd [<xref ref-type="bibr" rid="canavan.REF.kaul.1993.118">Kaul et al 1993</xref>]. The 93% homology of the amino acid and nucleotide sequence of human and bovine aspartoacylase suggest a high degree of conservation of this enzyme in mammals [<xref ref-type="bibr" rid="canavan.REF.kaul.1994a.364">Kaul et al 1994a</xref>]. The protein is observed in most tissues.</p>
        <p>Recent studies have shown that ASPA is a dimer with zinc at the catalytic site analogous to other carboxypeptidases. Pathogenic variants caused conformational changes that affect the activity of the enzyme [<xref ref-type="bibr" rid="canavan.REF.bitto.2007.456">Bitto et al 2007</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Aspartoacylase is responsible for hydrolyzing N-acetylaspartic acid (NAA) into aspartic acid and acetate. The abnormal alleles include null variants, which make no aspartoacylase, and missense variants, which make less active forms of aspartoacylase. Although aspartoacylase is expressed widely throughout the body, its absence in the CNS leads to the specific build-up of NAA in the brain that causes demyelinization and other signs of the disease.</p>
      </sec>
      <sec id="canavan.References">
        <title>References</title>
        <sec id="canavan.Published_GuidelinesConsensus_St">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="canavan.Published_GuidelinesConsensus_St.reflist0">
            <ref id="canavan.REF1">
              <mixed-citation publication-type="webpage">American College of Medical Genetics. Position statement on carrier testing for Canavan disease (pdf). Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acmg.net/StaticContent/StaticPages/Canavan.pdf">online</ext-link>.1998. Accessed 4-6-16.</mixed-citation>
            </ref>
            <ref id="canavan.REF.acog_committee_on_genetics.1999.91">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>ACOG Committee on Genetics</collab>
                </person-group>
                <article-title>ACOG committee opinion. Screening for Canavan disease. Number 212, November 1998. Committee on Genetics. American College of Obstetricians and Gynecologists.</article-title>
                <source>Int J Gynaecol Obstet.</source>
                <year>1999</year>
                <volume>65</volume>
                <fpage>91</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">10390111</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="canavan.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="canavan.Literature_Cited.reflist0">
            <ref id="canavan.REF.acog_committee_on_genetics.2009.950">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>ACOG Committee on Genetics</collab>
                </person-group>
                <year>2009</year>
                <article-title>ACOG committee opinion. Number 442, October. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent.</article-title>
                <source>Obstet Gynecol</source>
                <volume>114</volume>
                <fpage>950</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">19888064</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.aldirbashi.2009.477">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Al-Dirbashi</surname>
                    <given-names>OY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurdi</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imtiaz</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmad</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Sayed</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tulbah</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Nemer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rashed</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Reliable prenatal diagnosis of Canavan disease by measuring N-acetylaspartate in amniotic fluid using liquid chromatography tandem mass spectrometry.</article-title>
                <source>Prenat Diagn.</source>
                <volume>29</volume>
                <fpage>477</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">19235826</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.assadi.2010.354">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Assadi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldfarb</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suri</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilaniuk</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leone</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease.</article-title>
                <source>Eur J Paediatr Neurol.</source>
                <volume>14</volume>
                <fpage>354</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20034825</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.bennett.1993.831">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherwood</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Divry</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>ON</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Reliable prenatal diagnosis of Canavan disease (aspartoacylase deficiency): comparison of enzymatic and metabolite analysis.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>16</volume>
                <fpage>831</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8295397</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.bitto.2007.456">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bitto</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bingman</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wesenberg</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCoy</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>GN</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>104</volume>
                <fpage>456</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">17194761</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.breitbachfaller.2003.96">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Breitbach-Faller</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schrader</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rating</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wunsch</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Ultrasound findings in follow-up investigations in a case of aspartoacylase deficiency (canavan disease).</article-title>
                <source>Neuropediatrics</source>
                <volume>34</volume>
                <fpage>96</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12776232</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.elpeleg.1999.531">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>ON</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaag</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>22</volume>
                <fpage>531</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10407784</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.fares.2008.236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fares</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badarneh</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abosaleh</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harari-Shaham</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diukman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Carrier frequency of autosomal-recessive disorders in the Ashkenazi Jewish population: should the rationale for mutation choice for screening be reevaluated?</article-title>
                <source>Prenat Diagn.</source>
                <volume>28</volume>
                <fpage>236</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">18264947</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.feigenbaum.2004.142">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Feigenbaum</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hewson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chitayat</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ray</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockley</surname>
                    <given-names>TL</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>124A</volume>
                <fpage>142</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">14699612</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.janson.2002.1391">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Janson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McPhee</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilaniuk</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haselgrove</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testaiuti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freese</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shera</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hurh</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rupin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saslow</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldfarb</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldberg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larijani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharrar</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liouterman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camp</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolodny</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samulski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leone</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.</article-title>
                <source>Hum Gene Ther</source>
                <volume>13</volume>
                <fpage>1391</fpage>
                <lpage>412</lpage>
                <pub-id pub-id-type="pmid">12162821</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.kaul.1994a.364">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaul</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balamurugan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1994a</year>
                <article-title>Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution.</article-title>
                <source>Genomics</source>
                <volume>21</volume>
                <fpage>364</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">8088831</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.kaul.1994b.34">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaul</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aloya</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balamurugan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrosky</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michals</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1994b</year>
                <article-title>Canavan disease: mutations among Jewish and non-jewish patients.</article-title>
                <source>Am J Hum Genet</source>
                <volume>55</volume>
                <fpage>34</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">8023850</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.kaul.1993.118">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaul</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balamurugan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.</article-title>
                <source>Nat Genet</source>
                <volume>5</volume>
                <fpage>118</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">8252036</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.kaya.2008.675">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaya</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imtiaz</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colak</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Sayed</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Odaib</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Zahrani</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Mubarak</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Owain</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Dhalaan</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chedrawi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Hassnan</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coskun</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakati</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozand</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>BF</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Genome-wide gene expression profiling and mutation analysis of Saudi patients with Canavan disease.</article-title>
                <source>Genet Med</source>
                <volume>10</volume>
                <fpage>675</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">18978679</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.kronn.1995.1250">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kronn</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oddoux</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ostrer</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population</article-title>
                <comment>[letter]</comment>
                <source>Am J Hum Genet</source>
                <volume>57</volume>
                <fpage>1250</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">7485179</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.kurczynski.2011">
              <mixed-citation publication-type="confproc">Kurczynski TW, Victorio MC. Atypical Canavan disease associated with a p.A305E mutation and a p.P257R novel variant in the aspartoacylase gene. Abstract 312. Vancouver, Canada: American College of Medical Genetics Annual Clinical Genetics Meeting; 2011.</mixed-citation>
            </ref>
            <ref id="canavan.REF.leone.2000.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leone</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janson</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilaniuk</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorgi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaul</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeng</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freese</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McPhee</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mee</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>During</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilianuk</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease.</article-title>
                <source>Ann Neurol</source>
                <volume>48</volume>
                <fpage>27</fpage>
                <lpage>38</lpage>
                <pub-id pub-id-type="pmid">10894213</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.madhavarao.2009.640">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Madhavarao</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arun</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anikster</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mog</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Staretz-Chacham</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moffett</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grunberg</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Namboodiri</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>32</volume>
                <fpage>640</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">19685155</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.matalon.1993.744">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaul</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michals</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Canavan disease: biochemical and molecular studies.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>16</volume>
                <fpage>744</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">8412017</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.matalon.1995.511">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michals</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaul</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Canavan disease: from spongy degeneration to molecular analysis.</article-title>
                <source>J Pediatr</source>
                <volume>127</volume>
                <fpage>511</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">7562269</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.matalon.1998.69">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michals-Matalon</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Molecular basis of Canavan disease.</article-title>
                <source>Eur J Paediatr Neurol</source>
                <volume>2</volume>
                <fpage>69</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">10724099</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.matalon.2000.165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rady</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platt</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skinner</surname>
                    <given-names>HB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quast</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceci</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyring</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nehls</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Surendran</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ezell</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szucs</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.</article-title>
                <source>J Gene Med</source>
                <volume>2</volume>
                <fpage>165</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">10894262</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.matalon.2003.580">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Surendran</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rady</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quast</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyring</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peden</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ezell</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muzyczka</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.</article-title>
                <source>Mol Ther</source>
                <volume>7</volume>
                <fpage>580</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12718900</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.matalon.2000.d307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michals-Matalon</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings.</article-title>
                <source>Front Biosci</source>
                <volume>5</volume>
                <fpage>D307</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">10704428</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.mcphee.2006.577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McPhee</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janson</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samulski</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camp</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shera</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lioutermann</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feely</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freese</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leone</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Immune responses to AAV in a phase I study for Canavan disease.</article-title>
                <source>J Gene Med.</source>
                <volume>8</volume>
                <fpage>577</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">16532510</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.michals.2011">
              <mixed-citation publication-type="book">Michals K, Matalon R. Canavan disease. In: Raymond GV, Eichler F, Fatemi A, Naidu S, eds. <italic toggle="yes">Leukodystrophies</italic>. London: Mac Keith Press, 2011:156-69.</mixed-citation>
            </ref>
            <ref id="canavan.REF.olsen.2002.e55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Olsen</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tranebjaerg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kvittingen</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagenfeldt</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moller</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nilssen</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Two novel aspartoacylase gene (ASPA) missense mutations specific to Norwegian and Swedish patients with Canavan disease.</article-title>
                <source>J Med Genet</source>
                <volume>39</volume>
                <fpage>e55</fpage>
                <pub-id pub-id-type="pmid">12205125</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.sugarman.2001.s38">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sugarman</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allitto</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Carrier testing for seven diseases common in the Ashkenazi Jewish population: implications for counseling and testing.</article-title>
                <source>Obstet Gynecol</source>
                <volume>97</volume>
                <fpage>S38</fpage>
                <lpage>S39</lpage>
              </element-citation>
            </ref>
            <ref id="canavan.REF.surendran.2003.809">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Surendran</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bamforth</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyring</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodman</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Mild elevation of N-acetylaspartic acid and macrocephaly: diagnostic problem.</article-title>
                <source>J Child Neurol</source>
                <volume>18</volume>
                <fpage>809</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">14696913</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.surendran.2004.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Surendran</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shihabuddin</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taksir</surname>
                    <given-names>TV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parsons</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyring</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michals-Matalon</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mouse neural progenitor cells differentiate into oligodendrocytes in the brain of a knockout mouse model of Canavan disease.</article-title>
                <source>Brain Res Dev Brain Res</source>
                <volume>153</volume>
                <fpage>19</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">15464214</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.tacke.2005.252">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tacke</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olbrich</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sass</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fekete</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziyeh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleijer</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Payne</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vargiami</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zafeiriou</surname>
                    <given-names>DI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Omran</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease.</article-title>
                <source>Neuropediatrics</source>
                <volume>36</volume>
                <fpage>252</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16138249</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.traka.2008.11537">
              <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Traka</surname><given-names>M</given-names></name><name name-style="western"><surname>Wollmann</surname><given-names>RL</given-names></name><name name-style="western"><surname>Cerda</surname><given-names>SR</given-names></name><name name-style="western"><surname>Dugas</surname><given-names>J</given-names></name><name name-style="western"><surname>Barres</surname><given-names>BA</given-names></name></person-group>PopKo B<year>2008</year><article-title>Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.</article-title><source>J Neurosci</source><volume>28</volume><fpage>11537</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">18987190</pub-id></mixed-citation>
            </ref>
            <ref id="canavan.REF.yalcinkaya.2005.336">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yalcinkaya</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benbir</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karaarslan</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Atypical MRI findings in Canavan disease: a patient with a mild course.</article-title>
                <source>Neuropediatrics</source>
                <volume>36</volume>
                <fpage>336</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16217711</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.yaron.2005.465">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yaron</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mey-Raz</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amit</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lessing</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malcov</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Preimplantation genetic diagnosis of Canavan disease.</article-title>
                <source>Fetal Diagn Ther</source>
                <volume>20</volume>
                <fpage>465</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16113575</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.zano.2011.176">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malik</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szucs</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viola</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease.</article-title>
                <source>Mol Genet Metab</source>
                <volume>102</volume>
                <fpage>176</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">21095151</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.zeng.2002.557">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zeng</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>ZH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leone</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Gasperi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raghavan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ong</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolodny</surname>
                    <given-names>EH</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>25</volume>
                <fpage>557</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">12638939</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.zeng.2006.156">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zeng</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>ZH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leone</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raghavan</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolodny</surname>
                    <given-names>EH</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Rapid detection of three large novel deletion of the aspartoacylase gene in non-jewish patients with Canavan disease.</article-title>
                <source>Mol Genet Metab</source>
                <volume>89</volume>
                <fpage>156</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">16854607</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="canavan.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="canavan.Suggested_Reading.reflist0">
            <ref id="canavan.REF.arun.2010.195">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arun</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madhavarao</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moffett</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamilton</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grunberg</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ariyannur</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anikster</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mog</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hallows</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Denu</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Namboodiri</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>33</volume>
                <fpage>195</fpage>
                <lpage>210</lpage>
                <pub-id pub-id-type="pmid">20464498</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.baslow.2002.403">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baslow</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitada</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suckow</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hungund</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serikawa</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats.</article-title>
                <source>Neurochem Res.</source>
                <year>2002</year>
                <volume>27</volume>
                <fpage>403</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12064356</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.janson.2006.428">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Janson</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolodny</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeng</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raghavan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assadi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McPhee</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldfarb</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saslow</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freese</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilaniuk</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shera</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leone</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene.</article-title>
                <source>Ann Neurol.</source>
                <year>2006</year>
                <volume>59</volume>
                <fpage>428</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">16437572</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.kitada.2000.2512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kitada</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akimitsu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shigematsu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maihara</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yokoi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuramoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serikawa</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system.</article-title>
                <source>J Neurochem.</source>
                <volume>74</volume>
                <fpage>2512</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10820213</pub-id>
              </element-citation>
            </ref>
            <ref id="canavan.REF.matalon.2008.28">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhatia</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzucs</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michals-Matalon</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyring</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grady</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Aspartoacylase entry to the brain of Canavan mouse with hyaluronidase?</article-title>
                <source>J Inherit Metab. Dis.</source>
                <volume>31</volume>
                <fpage>28</fpage>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="canavan.Chapter_Notes">
        <title>Chapter Notes</title>
        <p>
          <bold>Author History</bold>
        </p>
        <p>Gita Bhatia, PhD; University of Texas Medical Branch (2009-2011)Kimberlee Michals-Matalon, PhD, RD (2011-present)Reuben Matalon, PhD (1999-present)</p>
        <sec id="canavan.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>11 August 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>1 October 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>15 March 2006 (cd) Revision: deletion/duplication analysis clinically available</p>
            </list-item>
            <list-item>
              <p>30 December 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>7 November 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>3 October 2001 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>16 September 1999 (pb) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>17 April 1999 (rm) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
